Chronic myelogenous leukemia is a myeloproliferative disorder. It is characterized by a
biphasic or triphasic clinical course in which a benign chronic phase is followed by …

Abstract Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …

Chronic myelogenous leukemia (CML) is a chronic myeloproliferative disorder with an
initially chronic course lasting for 3–5 years. It eventually transforms into accelerated and …

(Ph)-positive chronic myelogenous leukemia (CML) have matured. These include single and
multi-institutional programs with allogeneic bone marrow transplantation (BMT), interferon-a …

The prognosis of patients with chronic myelogenous leukemia (CML) has significantly
improved over the last 20 years. Whereas the median survival durations were 4-5 years in …

Interferon-alpha (IFNα) was once the standard of frontline treatment for chronic myeloid
leukemia (CML). Its pleiotropic mechanism of action in CML includes immune activation and …

Biological agents have long been used in the treatment of cancer, and interferon-alpha was
the first human cytokine to be widely studied in this setting. Chronic myeloid leukemia (CML) …

PURPOSE: To evaluate the efficacy of the combination of interferon alpha (IFN-α) and daily
low-dose cytarabine (ara-C) in the treatment of patients with early chronic-phase chronic …

IFNs were the first new therapeutic products resulting from recombinant DNA technology.
IFNs were also the first human proteins effective in cancer treatment. There is however much …

The prognosis for patients with chronic myelogenous leukemia (CML) has changed
markedly since 1856, when the use of arsenicals (Fowler's solution) was first advocated in …